Literature DB >> 17623032

Interleukin-12p40 overexpression promotes interleukin-12p70 and interleukin-23 formation but does not affect bacille Calmette-Guérin and Mycobacterium tuberculosis clearance.

Maria L Olleros1, Dominique Vesin, Eduardo Martinez-Soria, Cindy Allenbach, Fabienne Tacchini-Cottier, Jean-Claude Pache, Gilles Marchal, Jubayer Rahman, Carmen Fernández, Shozo Izui, Irene Garcia.   

Abstract

Interleukin (IL)-12p40, a subunit of IL-12p70 and IL-23, has previously been shown to inhibit IL-12p70 activity and interferon-gamma (IFN-gamma) production. However, recent evidence has suggested that the role of IL-12p40 is more complex. To study the contribution of IL-12p40 to immune responses against mycobacterial infections, we have used transgenic (tg) mice overexpressing IL-12p40 under the control of a major histocompatibility complex-II promoter. The IL-12p40 transgene was expressed during steady state at concentrations of 129 +/- 25 ng/ml of serum and 75 +/- 13 ng per spleen, while endogenous IL-12p40 was hardly detectable in control littermates. Bacille Calmette-Guérin (BCG) infection strongly induced the expression of IL-12p40 transgene in infected organs, and IL-12p40 monomeric and dimeric forms were identified in spleen of IL-12p40 tg mice. Excessive production of IL-12p40 resulted in a 14-fold increase in IL-12p70 serum levels in tg mice versus non-transgenic mice. IL-23 was also strongly elevated in the serum and spleens of IL-12p40 tg mice through BCG infection. While IFN-gamma and tumour necrosis factor protein levels were similar in IL-12p40 tg and non-transgenic mice, Th2 type immune responses were reduced in IL-12p40 tg mice. The number of BCG granulomas and macrophage expressing inducible nitric oxide synthase were similar in IL-12p40 tg and non-transgenic mice. IL-12p40 tg mice were as resistant as non-transgenic mice to BCG and Mycobacterium tuberculosis infections as they could efficiently control bacillary growth. These data show that high amounts of IL-12p40 promotes IL-12p70 and IL-23 formation, but that does not affect T helper 1 type immune responses and granuloma function, thus leading to normal mycobacterial clearance in infected organs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623032      PMCID: PMC2266026          DOI: 10.1111/j.1365-2567.2007.02646.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present.

Authors:  Andrea M Cooper; Andre Kipnis; Joanne Turner; Jeanne Magram; Jessica Ferrante; Ian M Orme
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

2.  Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

Authors:  Maria L Olleros; Reto Guler; Nadia Corazza; Dominique Vesin; Hans-Pietro Eugster; Gilles Marchal; Pierre Chavarot; Christoph Mueller; Irene Garcia
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

3.  A protective and agonistic function of IL-12p40 in mycobacterial infection.

Authors:  C Hölscher; R A Atkinson; B Arendse; N Brown; E Myburgh; G Alber; F Brombacher
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

4.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

5.  Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection.

Authors:  Alissa A Chackerian; Shi-Juan Chen; Scott J Brodie; Jeanine D Mattson; Terrill K McClanahan; Robert A Kastelein; Edward P Bowman
Journal:  Infect Immun       Date:  2006-08-21       Impact factor: 3.441

6.  Lethal Mycobacterium bovis Bacillus Calmette Guérin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2.

Authors:  I Garcia; R Guler; D Vesin; M L Olleros; P Vassalli; Y Chvatchko; M Jacobs; B Ryffel
Journal:  Lab Invest       Date:  2000-09       Impact factor: 5.662

7.  A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection.

Authors:  R Lucas; F Tacchini-Cottier; R Guler; D Vesin; S Jemelin; M L Olleros; G Marchal; J L Browning; P Vassalli; I Garcia
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

8.  TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.

Authors:  Daniel R Roach; Andrew G D Bean; Caroline Demangel; Malcolm P France; Helen Briscoe; Warwick J Britton
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.

Authors:  Daniel J Cua; Jonathan Sherlock; Yi Chen; Craig A Murphy; Barbara Joyce; Brian Seymour; Linda Lucian; Wayne To; Sylvia Kwan; Tatyana Churakova; Sandra Zurawski; Maria Wiekowski; Sergio A Lira; Daniel Gorman; Robert A Kastelein; Jonathon D Sedgwick
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

10.  Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes.

Authors:  Luc A Otten; Fabienne Tacchini-Cottier; Michael Lohoff; Francesco Annunziato; Lorenzo Cosmi; Leonardo Scarpellino; Jacques Louis; Viktor Steimle; Walter Reith; Hans Acha-Orbea
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

View more
  6 in total

1.  A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3.

Authors:  Amber M Smith; Joseph E Qualls; Kevin O'Brien; Liza Balouzian; Peter F Johnson; Stacey Schultz-Cherry; Stephen T Smale; Peter J Murray
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 2.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

3.  IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection.

Authors:  Sean Gunsten; Cassandra L Mikols; Mitchell H Grayson; Reto A Schwendener; Eugene Agapov; Rose M Tidwell; Carolyn L Cannon; Steven L Brody; Michael J Walter
Journal:  Immunology       Date:  2008-09-06       Impact factor: 7.397

4.  Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules.

Authors:  Maria L Olleros; Dominique Vesin; Ruth Bisig; Marie-Laure Santiago-Raber; Sonia Schuepbach-Mallepell; George Kollias; Olivier Gaide; Irene Garcia
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

5.  Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production.

Authors:  Dee N Dao; Kari Sweeney; Tsungda Hsu; Sudagar S Gurcha; Ivan P Nascimento; Dan Roshevsky; Gurdyal S Besra; John Chan; Steven A Porcelli; William R Jacobs
Journal:  PLoS Pathog       Date:  2008-06-06       Impact factor: 6.823

6.  Mycobacterium tuberculosis Rv0580c Impedes the Intracellular Survival of Recombinant Mycobacteria, Manipulates the Cytokines, and Induces ER Stress and Apoptosis in Host Macrophages via NF-κB and p38/JNK Signaling.

Authors:  Md Kaisar Ali; Lambert Nzungize; Khushnood Abbas; Nzaou Stech Anomene Eckzechel; M A Abo-Kadoum; Ulrich Aymard Ekomi Moure; Mohammed Asaad; Aftab Alam; Junqi Xu; Jianping Xie
Journal:  Pathogens       Date:  2021-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.